Simcere Pharmaceutical Group Limited (HK:2096) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Simcere Pharmaceutical Group Limited anticipates a revenue drop for the first half of 2024, with a projected 7.0% to 8.8% decrease compared to the previous year, primarily due to reduced promotion service revenue and changes in the COVID-19 situation affecting drug sales. Profits for the company are also expected to fall significantly by approximately 78.6% to 81.2%, largely influenced by a change in fair value of investments and the lack of one-off gains from subsidiary disposals that were present last year. These preliminary figures are based on unaudited accounts and subject to final adjustments with complete interim results to be released in late August 2024.
For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.